Related Experiment Video
Updated: Jun 14, 2026

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
Published on: August 25, 2021
RBFOX2 suppresses NETosis and glioma growth via 5hmC-dependent PDGFB decay
Xi Chen1, Weiwei Dai1, Hanlin Wang2
1Department of Pharmacology, School of Basic Medical Sciences, Shanghai Medical College, Fudan University, Shanghai 200032, China; Department of Microbiology, Key Laboratory of Medical Molecular Virology (Ministry of Education/ National Health Commission/ Chinese Academy of Medical Sciences), Shanghai Frontiers Science Center of Pathogenic Microorganisms and Infection, School of Basic Medical Sciences, Shanghai Medical College, Fudan University, Shanghai 200032, China; Nanhu Laboratory, Jiaxing, Zhejiang Province 314002, China.
Abstract:
Neutrophil extracellular traps (NETs) are increasingly recognized as key regulators of tumor progression, yet the molecular circuitry that governs their induction in cancer remains elusive. Here, we identify the RNA-binding protein RBFOX2 as a tumor suppressor that curtails glioma growth by coordinately restraining tumor cell proliferation and NETosis. RBFOX2 expression is markedly reduced in glioma and positively correlates with patient survival. Mechanistically, RBFOX2 binds to 5-hydroxymethylcytidine (5hmC)-modified sites within PDGFB mRNA and promotes its decay, thereby dampening AKT-SP1 signaling and repressing CSF3 transcription. This repression limits neutrophil-mediated NET formation in the tumor microenvironment, as confirmed in PAD4-/- mice and upon CSF3 neutralization. Collectively, our study uncovers a 5hmC-dependent post-transcriptional mechanism linking RBFOX2 to NETosis control and glioma suppression, revealing RBFOX2 as a potential biomarker and therapeutic lever and establishing a broader paradigm in which RNA-binding proteins couple post-transcriptional RNA modification and immune regulation in tumor evolution.
Insights
The RNA-binding protein RBFOX2 acts as a tumor suppressor in glioma by inhibiting cell growth and NETosis. Reduced RBFOX2 levels correlate with poor patient survival, highlighting its therapeutic potential.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- Neutrophil extracellular traps (NETs) play a role in tumor progression, but the mechanisms controlling their induction in cancer are not fully understood.
- Identifying regulators of NETosis in the tumor microenvironment is crucial for developing novel cancer therapies.
Purpose of the Study:
- To identify molecular mechanisms regulating NETosis in glioma.
- To investigate the role of the RNA-binding protein RBFOX2 in glioma progression and NETosis.
Main Methods:
- Analysis of RBFOX2 expression in glioma patient data.
- Investigating the interaction of RBFOX2 with PDGFB mRNA and its effect on mRNA decay.
- Assessing the impact of RBFOX2 on AKT-SP1 signaling and CSF3 transcription.
- Evaluating NET formation in vivo using PAD4-/- mice and CSF3 neutralization.
Main Results:
- RBFOX2 expression is significantly reduced in glioma and inversely correlates with patient survival.
- RBFOX2 binds to 5-hydroxymethylcytidine-modified PDGFB mRNA, promoting its decay.
- RBFOX2 represses CSF3 transcription, thereby limiting neutrophil-mediated NET formation.
- RBFOX2 restrains glioma cell proliferation and NETosis, acting as a tumor suppressor.
Conclusions:
- RBFOX2 functions as a tumor suppressor in glioma by controlling NETosis through a 5hmC-dependent post-transcriptional mechanism.
- RBFOX2 represents a potential biomarker and therapeutic target for glioma.
- This study establishes a link between RNA-binding proteins, RNA modification, and immune regulation in cancer evolution.
Related Concept Videos
Abnormal Proliferation
Hedgehog Signaling Pathway
Regulation of Angiogenesis and Blood Supply
